

*Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.*

*Neither this announcement nor any copy thereof may be released into or distributed directly or indirectly in the United States or any other jurisdiction where such release or distribution might be unlawful.*

*This announcement is for information purpose only and does not constitute an invitation or offer to acquire, purchase or subscribe for any securities of the Company.*

*This announcement is not, and does not form any part of, an offer or invitation for the sale of securities in the United States (as defined in Regulation S under the United States Securities Act of 1933 (the “**Securities Act**”)). Neither this announcement nor anything herein nor any copy thereof may be taken into or distributed, directly or indirectly, in or into the United States or any other jurisdiction where such release or distribution might be unlawful. The securities referred to herein have not been and will not be registered under the Securities Act, and may not be offered, sold or otherwise transferred within the United States unless the securities are registered under the Securities Act, or an exemption from the registration requirements of the Securities Act is available. The Company does not intend to register any securities described herein in the United States or to make any public offering of the securities in the United States.*



**WUXI APPTEC CO., LTD.\***

**無錫藥明康德新藥開發股份有限公司**

*(A joint stock company incorporated in the People's Republic of China with limited liability)  
(Stock Code: 2359)*

## **COMPLETION OF PLACING OF NEW H SHARES UNDER GENERAL MANDATE**

*Sole Overall Coordinator, Sole Global Coordinator and Lead Bookrunner*

# **Morgan Stanley**

*Joint Bookrunners*



**Goldman  
Sachs**



*(in alphabetical order)*

Reference is made to the announcement of WuXi AppTec Co., Ltd.\* (無錫藥明康德新藥開發股份有限公司) (the “**Company**”) dated July 31, 2025 in relation to the placing of the Placing Shares to be issued under the General Mandate (the “**Announcement**”). Unless otherwise defined, capitalized terms used herein shall have the same meanings as those defined in the Announcement.

## COMPLETION OF THE PLACING

The Board is pleased to announce that all the Conditions have been satisfied and the Completion took place on August 7, 2025. An aggregate of 73,800,000 Placing Shares have been successfully placed by the Placing Agents to no less than six independent Placees at the Placing Price of HK\$104.27 per Placing Share pursuant to the terms and conditions of the Placing Agreement. To the best of the knowledge, information and belief of the Directors, having made all reasonable enquiries, the Placees, together with their respective ultimate beneficial owners, are third parties independent of, and not connected with, the Company and the connected persons of the Company.

The net proceeds from the Placing are HK\$7,647,380,352.00, and will be utilized in the following manner:

- (a) approximately 90% will be used to accelerate global expansion and capacity construction; and
- (b) approximately 10% will be used for general corporate purposes.

The Placing Shares are issued under the General Mandate granted to the Directors by the Shareholders at the 2024 AGM held on April 29, 2025. Up to the date of this announcement, save for 1,078,548 H Shares which are reserved for issuance as the Additional Conversion Shares in the event of a full conversion of the outstanding Bonds at the Adjusted Conversion Price as a result of the 2024 Profit Distribution Plan and the 2025 Special Dividend Distribution (for details please refer to the relevant announcement of the Company dated May 23, 2025), no H Shares have been issued by the Company under the General Mandate. As such, as at the date of this announcement, the number of new H Shares that can be issued by the Company under the General Mandate is 76,336,682 H Shares (the “**Currently Available General Mandate**”). Following the Completion, the Company has utilized approximately 96.68% of the Currently Available General Mandate.

## EFFECT ON SHAREHOLDING STRUCTURE OF THE COMPANY

The shareholding structure of the Company (i) immediately prior to the Completion; and (ii) as at the date of this announcement are set out below.

Shareholders	Immediately prior to the Completion			As at the date of this announcement		
	<i>Class of Shares</i>	<i>Number of Shares</i>	<i>Approximate % of the total issued share capital</i>	<i>Class of Shares</i>	<i>Number of Shares</i>	<i>Approximate % of the total issued share capital</i>
The shareholders controlled by the de facto controllers of the Company, the shareholders who have signed a concert party agreement with the de facto controllers and the shareholder who has signed a voting proxy agreement with the de facto controllers <sup>(Note 1)</sup>	A Shares	593,458,536	20.66%	A Shares	593,458,536	20.14%
Other holders of A Shares	A Shares	1,891,682,519	65.86%	A Shares	1,891,682,519	64.21%
Holders of H Shares <sup>(Note 2)</sup>	H Shares	387,076,150	13.48%	H Shares	387,076,150	13.14%
The Placees	—	—	—	H Shares	73,800,000	2.51%
<b>Total</b>	<b>—</b>	<b>2,872,217,205</b>	<b>100.00%</b>	<b>—</b>	<b>2,946,017,205</b>	<b>100.00%</b>

Notes:

- (1) Dr. Ge Li, Mr. Zhaohui Zhang and Mr. Xiaozhong Liu signed an acting-in-concert agreement pursuant to which as shareholders and directors of the Company, they will act in concert on all decision-making matters at the Shareholder's general meetings and Board meetings, and will act as the de facto controllers of the Company. The de facto controllers of the Company jointly control a total of 20.14% of the voting rights of the Company through the shareholders controlled by them as at the date of this announcement, the shareholders who have signed a concert party agreement with the de facto controllers and the shareholder who has signed a voting proxy agreement with the de facto controllers. This offering will not result in change of the de facto controllers of the Company.
- (2) An aggregate of 530,896 H Shares, being vested portion of awards granted under the H share award and trust schemes adopted by the Company, are beneficially owned by Dr. Ge Li.
- (3) The discrepancies between the total and sums of amounts in the table above are due to rounding.

By order of the Board  
**WuXi AppTec Co., Ltd.\***  
**Dr. Ge Li**  
*Chairman*

Hong Kong, August 7, 2025

*As at the date of this announcement, the Board comprises Dr. Ge Li, Dr. Minzhang Chen, Dr. Steve Qing Yang and Mr. Zhaohui Zhang as executive Directors, Mr. Xiaomeng Tong and Dr. Yibing Wu as non-executive Directors and Ms. Christine Shaohua Lu-Wong, Dr. Wei Yu, Dr. Xin Zhang, Ms. Zhiling Zhan and Mr. Xuesong Leng as independent non-executive Directors.*

\* For identification purposes only